Overview

  • Product name
    Anti-JAM-C antibody [19 H36]
    See all JAM-C primary antibodies
  • Description
    Rat monoclonal [19 H36] to JAM-C
  • Host species
    Rat
  • Tested applications
    Suitable for: IP, Flow Cyt, IHC-Frmore details
    Unsuitable for: IHC-P or WB
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    This information is considered to be commercially sensitive.

  • Positive control
    • High endothelial venules of lymphoid organs, lymphoendothelial cells and endothelial cells of the kidney
  • General notes

    Previously labelled as Junctional Adhesion Molecule C.

Properties

Applications

Our Abpromise guarantee covers the use of ab16889 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP Use at an assay dependent concentration.
Flow Cyt Use at an assay dependent concentration.

ab18450 - Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.

 

IHC-Fr Use at an assay dependent concentration.
  • Application notes
    Is unsuitable for IHC-P or WB.
  • Target

    • Function
      Participates in cell-cell adhesion. It is a counterreceptor for ITGAM, mediating leukocyte-platelet interactions and is involved in the regulation of transepithelial migration of polymorphonuclear neutrophils (PMN). The soluble form is a mediator of angiogenesis.
    • Tissue specificity
      Highest expression in placenta, brain and kidney. Significant expression is detected on platelets. Expressed in intestinal mucosa cells. Expressed in the vascular endothelium. Found in serum (at protein level). Also detected in the synovial fluid of patients with rheumatoid arthritis, psoriatic arthritis or ostearthritis (at protein level).
    • Involvement in disease
      Defects in JAM3 are the cause of hemorrhagic destruction of the brain with subependymal calcification and cataracts (HDBSCC) [MIM:613730]. A syndrome characterized by congenital cataracts and severe brain abnormalities apparently resulting from hemorrhagic destruction of the brain tissue, including the cerebral white matter and basal ganglia. Patients manifest profound developmental delay, and other neurologic features included seizures, spasticity, and hyperreflexia. Brain imaging shows multifocal intraparenchymal hemorrhage with associated liquefaction and massive cystic degeneration, and calcification in the subependymal region and in brain tissue.
    • Sequence similarities
      Belongs to the immunoglobulin superfamily.
      Contains 1 Ig-like C2-type (immunoglobulin-like) domain.
      Contains 1 Ig-like V-type (immunoglobulin-like) domain.
    • Post-translational
      modifications
      Proteolytically cleaved from endothelial cells surface into a soluble form by ADAM10 and ADAM17; the release of soluble JAM3 is increased by proinflammatory factors.
    • Cellular localization
      Cell membrane. Cell junction > desmosome. Secreted > extracellular space. In epithelial cells, it is expressed at desmosomes but not at tight junctions. Localizes at the cell surface of endothelial cells; treatment of endothelial cells with vascular endothelial growth factor stimulates recruitement of JAM3 to cell-cell contacts.
    • Information by UniProt
    • Database links
    • Alternative names
      • FLJ14529 antibody
      • JAM 2 antibody
      • JAM 3 antibody
      • JAM C antibody
      • JAM-2 antibody
      • JAM-3 antibody
      • JAM-C antibody
      • JAM2 antibody
      • Jam3 antibody
      • JAM3_HUMAN antibody
      • JAMC antibody
      • Junctional adhesion molecule 3 antibody
      • Junctional adhesion molecule 3 precursor antibody
      • Junctional adhesion molecule C antibody
      see all

    References

    ab16889 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    1-2 of 2 Abreviews or Q&A

    Answer

    Thank you once again for your recent enquiries. I have investigated this case and have obtained the following information for you regarding out JAMC and JAM 2 antibodies. I can understand the confusion, and hope this will help. The SwissProt/Uniprot entry for JAM C states this as JAM 3 and JAM 2, which is where some of the confusion may be. The SwisProt/Uniprot entry link on the datasheet will be the correct one for the target of that antibody. I can confirm the following: ab16906 Junctional Adhesion Molecule C antibody [CRAM-18 F26]        This is detecting JAM 3, Junctional adhesion molecule C. The correct Swissprot/Uniprot ID is on the datasheet: http://www.uniprot.org/uniprot/Q9BX67 http://www.uniprot.org/uniprot/B3KWG9 ab22539 Junctional Adhesion Molecule 2 antibody [CRAM-18 F26]    This is the same clone, detecing JAM 3. junctional adhesion molecule C. http://www.uniprot.org/uniprot/Q9D8B7 (I have requested that the SwissProt/Uniprot ID link on our datasheet is corrected as I as there has been an error with this entry on the datasheet, my apologies) ab23643 Junctional Adhesion Molecule 2 antibody [CRAM-19 H36]     This is a different clone. It detects JAM 2, or JAM C. http://www.uniprot.org/uniprot/P57087 ab16889 Junctional Adhesion Molecule C antibody [19 H36]     Regrettably, I am sorry we had the incorrect clone number for this antibody. I have been informed this this is clone [19 H36]. This is detecting JAM C (JAM 3). http://www.uniprot.org/uniprot/B3KWG9 I hope this will be helpful. If you have any further questions, please do not hesitate to contact us.

    Read More

    Answer

    I'm sorry you have been experiencing a problem with ab16889. As positive control for staining JAM-2 on frozen sections murine tissue of high endothelial venules of lymphoid organs can be used. Or lymphoendothelial cells and the endothelial cells of the kidney. Because this antibody is cross-reactive with human it is possible to use human HUVEC monolayers as positive control to. I would recommend the following modifications to your protocol to improve the staining: -try fresh frozen sections postfixed with methanol (10min), -block with normal serum -incubate the primary antibody overnight in PBST -try with biotin-ABC-DAB detection rather than IF -make sure the amount of tritonx100 in the dilution and blocking buffer is adequate, typically 0.3% v/v in PBS. I hope these suggestions will help, please do not hesitate to contact us if you require further assistance,

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up